(Reuters) - Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, ...

"According to the latest study from BCC Research, Antibody Drugs: Technologies and Global Markets is expected to grow from $242.6 billion in 2024 to $412.1 billion ...

The event provided a platform to reflect on the foundation’s accomplishments, unveil a new logo, vision, and mission statement, and launch its Y’ello Impact Report, reinforcing its commitment ...

We have established a robust foundation with Farxiga ... Tezspire is on its way to become a $1 billion brand together with our colleagues of Amgen. Specifically regarding Symbicort, I think it's fair ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA.

Congress requires federal agencies to solicit the public’s views, in the form of comment letters, before they issue regulations. Heritage scholars regularly file comments on proposed regulations.